Zhu XL - Search Results

1

Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.

Jin ZC, Chen L, Zhong BY, Zhu HD, Zeng CH, Li R, Guo JH, He SC, Deng G, Zhu XL, Ni CF, Teng GJ. Jin ZC, et al. Among authors: zhu xl, zhu hd. Front Oncol. 2021 May 6;11:602700. doi: 10.3389/fonc.2021.602700. eCollection 2021. Front Oncol. 2021. PMID: 34026598 Free PMC article.

2

Treatment strategies and indications for interventional management of pseudoaneurysms.

Zhu XL, Ni CF, Liu YZ, Jin YH, Zou JW, Chen L. Zhu XL, et al. Chin Med J (Engl). 2011 Jun;124(12):1784-9. Chin Med J (Engl). 2011. PMID: 21740833

3

Embolization of arterial gastrointestinal hemorrhage with Fuaile medical adhesive.

Xu M, Zhu X, Liu Y, Li Z, An T, Jiang T, Song J, Wang L, Zhou S, Ni C. Xu M, et al. J Chin Med Assoc. 2018 Jul;81(7):636-642. doi: 10.1016/j.jcma.2017.10.006. Epub 2017 Dec 1. J Chin Med Assoc. 2018. PMID: 29198548 Free article.

4

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.

Wang K, Jiang G, Jia Z, Zhu X, Ni C. Wang K, et al. Medicine (Baltimore). 2018 Jun;97(22):e10940. doi: 10.1097/MD.0000000000010940. Medicine (Baltimore). 2018. PMID: 29851833 Free PMC article.

5

Increased expression of epidermal growth factor-like domain-containing protein 7 is predictive of poor prognosis in patients with hepatocellular carcinoma.

Yang C, Wang YL, Sun D, Zhu XL, Li Z, Ni CF. Yang C, et al. Among authors: zhu xl. J Cancer Res Ther. 2018;14(4):867-872. doi: 10.4103/jcrt.JCRT_745_17. J Cancer Res Ther. 2018. PMID: 29970668 Free article.

6

EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.

Li Z, Xue TQ, Yang C, Wang YL, Zhu XL, Ni CF. Li Z, et al. Among authors: zhu xl. J Cell Biochem. 2018 Dec;119(12):10327-10337. doi: 10.1002/jcb.27375. Epub 2018 Aug 20. J Cell Biochem. 2018. PMID: 30129142

7

Feasibility of Helical I-125 Seed Implant in the Portal Vein.

Wang C, Wang W, Shen J, Ren B, Zhu X, Ni C. Wang C, et al. Cardiovasc Intervent Radiol. 2019 Jan;42(1):121-129. doi: 10.1007/s00270-018-2059-0. Epub 2018 Aug 30. Cardiovasc Intervent Radiol. 2019. PMID: 30167775

8

High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization.

Shen J, Wang WS, Zhu XL, Ni CF. Shen J, et al. Among authors: zhu xl. J Vasc Interv Radiol. 2018 Dec;29(12):1678-1684. doi: 10.1016/j.jvir.2018.07.030. Epub 2018 Nov 2. J Vasc Interv Radiol. 2018. PMID: 30392801

9

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study.

Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Ren B, et al. J Cancer. 2019 Jan 29;10(5):1189-1196. doi: 10.7150/jca.28994. eCollection 2019. J Cancer. 2019. PMID: 30854128 Free PMC article.

10

Safety and Feasibility of Helical I-125 Seed Implants Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas with Main Portal Vein Tumor Thrombus.

Wang W, Shen J, Wang C, Ren B, Zhu X, Ni C. Wang W, et al. Cardiovasc Intervent Radiol. 2019 Oct;42(10):1420-1428. doi: 10.1007/s00270-019-02256-z. Epub 2019 Jun 11. Cardiovasc Intervent Radiol. 2019. PMID: 31187228

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

988 results

Search Page

Filters